mRNA

The U.S. Food and Drug Administration (FDA) expanded approval of Moderna Inc.’s (NASDAQ:MRNA) respiratory syncytial virus vaccine to adults aged 18-59 at increased risk for disease. What Happened: The FDA on Thursday approved broader use of Moderna’s mRESVIA vaccine for younger at-risk...

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction. According to the agreement, shareholders can exchange CureVac shares for around $5.46 in BioNTech ADSs. This equates, roughly, to an equity value of $1.25 billion. The consideration...

GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a Delaware federal court, alleging patent infringement concerning mRNA technology used in the COVID-19 vaccines.  The lawsuit contends that Pfizer...

Pharma companies across the globe, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in the fight against pathogens. The world learned about messenger RNA molecules and their ...

Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr. Anthony Fauci, who in his previous capacity as the director of the National Institute of Allergy And Infectious Diseases, spearheaded the vaccine drive against the pandemic. It came as a surprise that...

Moderna Inc (NASDAQ: MRNA) is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster. What Happened: The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S. Food and Drug Administration for evaluation of a booster...

The European Medicines Agency is investing a possible link between mRNA vaccines and erythema multiforme or two kidney disorders by a few recipients of the shots.   Europe's drug regulator has requested additional data from Pfizer Inc (NYSE: PFE), ...

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported a Q2 EPS loss of $(2.07), beating the consensus of $(2.14). The cash balance totaled $433.6 million. After the end of the quarter, Arcturus received the remaining $30 million of upfront payment from Vinbiocare.  The company...

Moderna Inc (NASDAQ: MRNA), a company founded in 2010, is now worth more than the 130-year old Merck & Co., Inc (NYSE: MRK) in terms of market capitalization. What Happened: Moderna’s shares spiked Monday amid a string of positive news including being granted provisional registration...

Novartis AG (NYSE: NVS) could get into the field of messenger ribonucleic acid (mRNA) technology, reported Reuters, citing Chairman Joerg Reinhardt in a newspaper interview. In the Aargauer Zeitung interview, Reinhardt also highlighted the company's interest in anti-infective...

Sanofi SA (NASDAQ: SNY) is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines. The company will invest approximately €400 million per year to build out its “end-to-end” internal capabilities in...

Translate Bio Inc (NASDAQ: TBIO) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Mutations in the genes that cause PCD result in ineffective mucociliary clearance,...

BioNTech SE (NASDAQ: BNTX) will set up its Southeast Asia headquarters in Singapore and build a manufacturing facility to produce its messenger RNA vaccines and other medicines to treat infectious diseases and cancer. The new site would produce hundreds of million doses of mRNA...